Chemical Formulation ChallengesCurrent formulations of sirolimus might not be suitable for long-term application due to chemical instability, poor solubility, and molecular weight, which presents challenges for commercial availability.
Financial PerformancePVLA reported a net loss of approximately $8.2M and an increase in R&D and G&A expenses.
Price TargetPrice target decreased by $1 to $52.